MedTrace Logo

Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

NCT05947448 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1215

Last updated 2024-04-01

No results posted yet for this study

Summary

This is a national multicenter, prospective, observational study. It is planned to enroll 1215 patients with newly diagnosed essential hypertension in 80 centers, and divide them into 3 groups according to different treatment plans given by doctors: AZL-M monotherapy group, CCB monotherapy group (amlodipine besylate tablets or nifedipine controlled-release tablets) and AZL-M+CCB (amlodipine besylate tablets or nifedipine controlled-release tablets) combined treatment group. Subjects were visited 4 times at baseline, 1 month, 3 months, and 6 months, and the following key indicators of subjects were measured according to the doctor's decision, and the measurement results were collected

Conditions

  • Essential Hypertension

Interventions

DRUG

Azilsartan Medoxomil Potassium Tablet

Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month

DRUG

Nifedipine Sustained -release Tablets

Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；

DRUG

Levoamlodipine Maleate Table

Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；

Sponsors & Collaborators

  • Hasten Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-22
Primary Completion
2025-06-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05947448 on ClinicalTrials.gov